"药物类别","药物","基因","检测位点","等级","检测结果","用药提示","毒副作用","药物敏感"
"铂类","cisplatin（顺铂）","XPC","rs2228001","1B","GG","使用顺铂治疗的患者，相比TT基因型，毒副作用风险可能较高","3","0"
"铂类","carboplatin（卡铂）","MTHFR","rs1801133","2A","AG","使用卡铂治疗的非小细胞肺癌患者，相比AA基因型，药物敏感性可能较低","0","1"
"铂类","Platinum compounds（铂类化合物）","GSTP1","rs1695","2A","AG","使用铂药物治疗的患者，相比GG基因型，毒副作用风险可能较高","3","0"
"铂类","Platinum compounds（铂类化合物）","XRCC1","rs1799782","NA","GG","使用铂药物治疗的非小细胞肺癌患者，相比AA/AG基因型，药物敏感性可能较低","0","1"
"铂类","cisplatin,platinum,Platinum compounds（顺铂、铂、铂化合物）","ERCC1","rs3212986","2B","CC","使用铂药物治疗的患者，相比AA基因型，毒副作用风险可能较高","3","0"
"铂类","carboplatin,cisplatin,oxaliplatin,platinum,Platinum compounds（卡铂、顺铂、奥沙利铂、铂、铂化合物）","ERCC1","rs11615","2B","GG","使用铂药物治疗的患者，相比AA基因型，毒副作用风险可能较低,药物敏感性可能较高","1","3"
"铂类","carboplatin,cisplatin,oxaliplatin,platinum,Platinum compounds（卡铂、顺铂、奥沙利铂、铂、铂化合物）","XRCC1","rs25487","2B","CC","使用铂药物治疗的患者，相比CT /TT基因型，毒副作用风险可能较高，药物敏感性可能较高","3","3"
"甲氨蝶呤","methotrexate（甲氨蝶呤）","MTHFR","rs1801133","3","AG","使用甲氨蝶蛉治疗的患者，相比AA基因型，毒副作用风险可能较低","1","0"
"甲氨蝶呤","methotrexate（甲氨蝶呤）","ATIC","rs4673993","2B","CT","使用甲氨蝶蛉治疗的患者，相比TT基因型，药物敏感性可能较高,相比CC基因型，药物敏感性可能较低","0","2"
"甲氨蝶呤","methotrexate（甲氨蝶呤）","MTRR","rs1801394","2B","AA","使用甲氨蝶蛉治疗的患者，相比GA/GG基因型，毒副作用风险可能较低","1","0"
"甲氨蝶呤","methotrexate（甲氨蝶呤）","ABCB1","rs1045642","2A","AG","使用甲氨蝶蛉治疗的患者，相比GG基因型，毒副作用风险可能较高","3","0"
"紫杉类","taxanes（紫杉烷类)","ABCB1","rs2032582","3","AC","使用紫杉烷治疗的患者，相比CC基因型，耐药风险可能较低","0","0"
"紫杉类","paclitaxel（紫杉醇)","ABCB1","rs1045642","3","AG","使用紫杉醇治疗的患者，相比GG基因型，毒副作用风险可能较高","3","0"
"紫杉类","paclitaxel and cisplatin (紫杉醇联合顺铂）","TP53","rs1042522","2B","CG","使用紫杉醇＋顺铂治疗的患者，相比CC基因型，药物敏感性可能较低","0","1"
"环磷酰胺","cyclophosphamide（环磷酰胺）","XRCC1","rs25487","3","CC","使用环磷酰胺为基础化疗的患者，相比CT/TT基因型，药物敏感性可能较高，毒副作用风险可能较高","3","3"
"环磷酰胺","cyclophosphamide（环磷酰胺）","MTHFR","rs1801133","2A","AG","使用环磷酰胺治疗的患者，相比AA基因型，毒副作用风险可能较低","1","0"
"环磷酰胺","cyclophosphamide（环磷酰胺）","SOD2","rs4880","2B","AA","使用环磷酰胺治疗的患者，相比GG基因型，药物敏感性可能较高","0","3"
"环磷酰胺","cyclophosphamide doxorubicin（环磷酰胺+多柔比星）","ABCB1","rs2032582","NA","AC","-","-","-"
"环磷酰胺","cyclophosphamide,epirubicin（环磷酰胺+表柔比星）","GSTP1","rs1695","2A","AG","使用环磷酰胺＋表阿霉素治疗的患者，相比GG基因型，药物敏感性可能较高，毒副作用风险可能较低","1","3"
"伊立替康","irinotecan（伊立替康）","UGT1A1","rs8175347","2A","6TA/6TA","使用伊立替康治疗的患者，相比7TA/7TA基因型，毒副作用风险可能较低","1","0"
"伊立替康","irinotecan（伊立替康）","UGT1A1","rs4148323","2A","AG","使用伊立替康基础治疗的患者，相比GG基因型，毒副作用风险可能较高,相比AA基因型，毒副作用风险可能较低","2","0"
"伊立替康","irinotecan（伊立替康）","C8orf34","rs1517114","2B","GG","使用伊立替康治疗的非小细胞肺癌患者，相比CC/CG基因型，毒副作用风险可能较低","1","0"
"依托泊苷","etoposide（依托泊苷）","SLIT1","rs2784917","4","AA","使用依托泊苷治疗的患者，相比AG/GG基因型，毒副作用风险可能较高","3","0"
"蒽环类","anthracyclines and related substances（蒽环类）","CBR3","rs1056892","2B","AG","使用蒽环类治疗的患者，相比AA基因型，毒副作用风险可能较高","3","0"
"卡培他滨","capecitabine（卡培他滨为基础化疗）","MTHFR","rs1801131","2A","TT","使用卡培他滨为基础的化疗，相比GG/GT基因型，毒副作用风险可能较低","1","0"
"卡培他滨","capecitabine,fluorouracil（卡培他滨为基础化疗）","DPYD","rs2297595","2A","TT","使用氟尿嘧啶或卡培他滨为基础治疗的患者，相比CC/CT基因型，毒副作用风险可能较低","1","0"
"卡培他滨","capecitabine,fluorouracil（5-fu或卡培他滨）","MTHFR","rs1801133","2A","AG","使用氟尿嘧啶或卡培他滨为基础治疗的患者，相比GG基因型，毒副作用风险可能较高，相比AA基因型，毒副作用风险可能较低","2","0"
"5-Fu、氟嘧啶类","fluorouracil,oxaliplatin（5-fu+奥沙利铂）","GSTP1","rs1695","2A","AG","使用氟尿嘧啶和奥沙利铂治疗的患者，相比AA基因型，药物敏感性可能较高,相比GG基因型，药物敏感性可能较低","0","2"
"5-Fu、氟嘧啶类","capecitabine,fluorouracil（5-fu单药或联合卡培他滨）","DPYD","rs2297595","2A","TT","使用氟尿嘧啶或卡培他滨为基础治疗的患者，相比CC/CT基因型，毒副作用风险可能较低","1","0"
"5-Fu、氟嘧啶类","capecitabine,fluorouracil（5-fu或卡培他滨）","MTHFR","rs1801133","2A","AG","使用氟尿嘧啶或卡培他滨为基础治疗的患者，相比GG基因型，毒副作用风险可能较高，相比AA基因型，毒副作用风险可能较低","2","0"
"5-Fu、氟嘧啶类","fluorouracil,leucovorin,tegafur（5-fu+亚叶酸或替加氟+亚叶酸）","UMPS","rs1801019","2B","GG","使用甲酰四氢叶酸和喃氟啶或氟尿嘧啶和亚叶酸治疗的患者,相比CC基因型，毒副作用风险可能较低","1","0"
"5-Fu、氟嘧啶类","capecitabine,fluorouracil,Pyrimidine analogues,tegafur(氟嘧啶为基础治疗)","DPYD","rs3918290","1A","CC","使用氟尿嘧啶为基础治疗的患者，相比CT/TT基因型，毒副作用风险可能较低","1","0"
"5-Fu、氟嘧啶类","capecitabine,fluorouracil,Pyrimidine analogues,tegafur(氟嘧啶为基础治疗)","DPYD","rs67376798","1A","TT","使用氟尿嘧啶为基础治疗的患者，相比AT基因型，毒副作用风险可能较低","1","0"
"5-Fu、氟嘧啶类","capecitabine,fluorouracil,Pyrimidine analogues,tegafur(氟嘧啶为基础治疗)","DPYD","rs55886062","1A","AA","使用氟尿嘧啶为基础治疗的患者，相比AC/CC基因型，毒副作用风险可能较低","1","0"
"吉西他滨","gemcitabine（吉西他滨）","CDA","rs2072671","2B","AA","使用吉西他滨治疗的患者，相比CC基因型，胃肠道毒性风险、中性粒细胞减少风险可能较低，血液学毒性风险可能较高","2","0"
"吉西他滨","gemcitabine（吉西他滨）","CDA","rs60369023","3","GG","使用吉西他滨治疗的患者，相比AA基因型，毒副作用风险可能较低","1","0"
"吉西他滨","gemcitabine（吉西他滨）","RRM1","rs9937","4","AG","使用吉西他滨治疗的患者，相比AA基因型，毒副作用风险可能较低","1","0"
"他莫昔芬","tamoxifen（他莫昔芬）","CYP2D6","rs3892097","2A","CC","使用他莫昔芬治疗的患者，相比TT基因型,复发风险可能降低，热潮红风险可能增高","0","0"
"他莫昔芬","tamoxifen(他莫昔芬)","CYP2D6","rs1065852","3","AG","使用他莫昔芬治疗的患者，相比含有等位基因G的基因型，复发风险可能较高","0","0"
"来曲唑","letrozole anastrozole（来曲唑、阿那曲唑）","CYP19A1","rs4646","3","CC","使用来曲唑治疗的患者，相比AA/AC基因型，药物敏感性可能较低","0","1"
